Home / Journals American Journal of Psychiatry and Neuroscience / Advancements and Implications of Psychedelics in Science, Practice, and Theory
Advancements and Implications of Psychedelics in Science, Practice, and Theory
Submission DeadlineMay 15, 2020

Submission Guidelines: http://www.sciencepublishinggroup.com/home/submission

Lead Guest Editor
Tyler Durns
University of Utah, Salt Lake City, Utah, USA
Guest Editor
Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to fulfill the Guest Editor application.
Introduction
The aim of this issue would be to evaluate the basic science and clinical implications of psychedelic use as an emerging therapy in psychiatric conditions. The pathophysiology of the various agents being studied across the world will be reviewed and included so as to offer insight into their influence on the brain (in regards to neural connectivity, neural activation, and molecular processing) and subsequent effect on disorders including but not limited to depression, anxiety, and addiction. There has been increasing discussion and debate over how many of these substances (psilocybin, lysergic acid diethylamide, N, N- Dimethyltryptamine, 3, 4- Methylenedioxymethamphetamine, and their active metabolites) may play a role in the treatment of psychiatric conditions. Much of the information available relies solely on clinical data, with there being a dearth of published data on the underlying mechanisms of these potential therapies, including functional neuroimaging and molecular studies that should be emphasized in this issue. However, clinical data underscoring the effects, risks, and benefits of these potential treatments are welcome as well. Concurrently, philosophical approaches to the use of psychedelics and conditions where they may be indicated will be examined, as is necessary in addressing these emerging and controversial treatments. There also exists potential to include information from varying philosophical perspectives and logistical complications in providing these therapies including legislative and systems issues that continue to impact scientific research and clinical care.
In summary the journal issue chiefly will:
  1. present emerging research on the pathophysiology of psychedelic compounds on the human brain and in animal models
  2. examine functional neuroimaging to elucidate the effect of psychedelic compounds
  3. review previous literature on the fundamental science and clinical findings of psychedelics in clinical practice
  4. assess philosophical approaches of the nosology and treatment for psychiatric illnesses with psychedelic compounds
  5. discuss ethical and logistical complications of the implementation of psychedelics
Aims and Scope:
  1. Psychedelics
  2. Emerging therapies
  3. Neurocircuitry
  4. Functional neuroimaging
  5. Philosophy/ethics
  6. Regulation
Guidelines for Submission
Manuscripts should be formatted according to the guidelines for authors
(see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=653).

Please download the template to format your manuscript.

ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186